Valuation dashboard for Impact BioMedical Inc. (IBO) with P/E N/A, P/B 4.56, EV/EBITDA -132.72 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions.
Analysis Summary
Trailing-twelve-month margins: gross margin -11.1%, operating margin -145.6%, net margin 22.5%.
At the current price of $0.50, IBO has negative trailing earnings (P/E not meaningful) and an ROE of 13.70%. Market capitalisation stands at $54M.
Balance sheet quality for IBO: current ratio of 0.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 4.56 |
| EV / EBITDA | -132.72 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-0.00 |
| vs Current Price | -100.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| IBO | Impact BioMedical Inc. | $54M | 4.56 | 13.7% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.50 |
| Market Cap | $54M |
| Exchange | AMEX |
| Country | US |
Profitability
| Return on Equity | 13.70% |
| Return on Invested Capital | 14.91% |
| Return on Assets | 4.71% |
| Gross Margin | -1111.43% |
| Operating Margin | -14562.86% |
| Net Margin | 2254.29% |
Related companies: ADIL · AIM · BCLI · CYCN · MLEC · NRSN · QNRX
Explore sector: Healthcare · Biotechnology
More sections of IBO: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks